BIOCANCELL THERAPEUTICS INC.
CIK 0001451980
Revenue (TTM)
—
Q1 May 2012
Net Income (TTM)
−$6.86M
−176.4% YoY
Q1 May 2012
EPS Diluted (TTM)
−$0.14
Q1 May 2012
Gross Margin
—
Q1 May 2012
Operating Margin
—
Q1 May 2012
Net Margin
—
Q1 May 2012
Free Cash Flow (TTM)
−$5.11M
Q1 May 2012
Cash
$1.59M
Q1 May 2012
Total Debt
—
Q1 May 2012
Shares Outstanding
39.39M sh
Q1 May 2012
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.